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Thesis Abstract 
 
 
The role of self-efficacy in Multiple Sclerosis  
This thesis aimed to explore the role of self-efficacy in Multiple Sclerosis. The thesis 
begins with a systematic literature review and meta-analysis to examine whether fatigue 
management interventions, based upon energy conservation strategies, increase self-
efficacy in people with Multiple Sclerosis experiencing fatigue. Three databases were 
searched, and a total of nine articles were identified as meeting the inclusion criteria. 
Meta-analysis revealed a medium effect of energy conservation interventions in reducing 
fatigue, and a large effect of energy conservation interventions in increasing self-efficacy. 
The findings from this systematic review suggest that energy conservation interventions 
are effective at increasing self-efficacy in people with Multiple Sclerosis, as well as 
reducing the impact of fatigue.  
The literature review is followed by an empirical paper, which aimed to investigate 
whether self-efficacy remains predictive of perceived cognitive impairment after 
controlling for objective cognitive functioning. This empirical paper also aimed to further 
explore the relationship between self-efficacy and cognitive domains (i.e., attention, 
processing speed, memory, and executive functioning), as measured objectively. A 
convenience sample of 25 adults with Multiple Sclerosis was recruited from a semi-rural 
part of North Wales. All participants completed a series of questionnaires and undertook 
a battery of neuropsychological assessments. Using hierarchical regression analyses, self-
efficacy was found to significantly predict perceived cognitive impairment, even after 
controlling for objective cognitive functioning. Correlational analyses also revealed a 
significant relationship between self-efficacy and processing speed, and self-efficacy and 
 VI 
executive function. The paper concludes that self-efficacy is associated with perceived 
cognitive impairment in people with Multiple Sclerosis, and therefore may be an 
important aspect of self-management programmes.   
The third chapter of this thesis addresses the implications for theory development and 
clinical practice, and future research. A reflective commentary is also enclosed.  
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Abstract 
 
Objective: To investigate whether fatigue management interventions, based upon 
energy conservation strategies, increase self-efficacy in people with Multiple 
Sclerosis experiencing fatigue. 
Data Sources: The Web of Science, PubMed, and PsycInfo databases were searched 
to identify relevant randomised controlled trials and single group design studies. The 
search was filtered to include English language articles only, and restricted to 
publications post-1950. An ancestral search was also conducted. The search identified 
a total of 75 articles. 
Study Selection: Inclusion criteria included quantitative experimental designs 
assessing both fatigue and self-efficacy pre- and post- a non-pharmacological 
intervention based upon energy conservation strategies. The first author reviewed the 
article’s title and abstract to determine whether the criteria for inclusion were met.  
Data Extraction: The first author extracted the relevant data and assessed the 
methodological quality of the studies, included in the meta-analysis, using the 
Evaluative method.  
Data Synthesis: Of the initial 75 studies, 9 were included in the review (n = 587). 
Two studies were assessed to have weak quality, five studies demonstrated adequate 
quality, and two studies were of strong quality. Meta-analyses revealed a medium 
effect of energy conservation interventions in reducing fatigue; pooled effect size of   
-0.39 (95% CI, -0.54 to -0.25, p = .001), and a large effect of energy conservation 
interventions in enhancing self-efficacy; with a pooled effect size of 0.53 (95% CI, 
11 
0.15 to 0.9, p = .01).  
 
Conclusions: The findings from this systematic review suggest that energy 
conservation interventions are effective at increasing self-efficacy in people with 
Multiple Sclerosis, as well as reducing the impact of fatigue. Future research may 
wish to examine whether increased self-efficacy is maintained at follow-up.  
Key Words: Meta-analysis, self-efficacy, fatigue, Multiple Sclerosis.  
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Multiple Sclerosis (MS) is a disease of the central nervous system causing 
inflammation, demyelination and destruction of axons within the brain and spinal 
cord. It is the most common neurological condition affecting young adults, with a 
typical onset between 20-40 years of age1. The disease presents as either relapsing-
remitting or progressive in nature; however often involves an accumulation of 
neurological deficits over time, resulting in cognitive and behavioural difficulties2. 
Symptomology varies depending upon the lesion site affected; yet common symptoms 
include weakness, stiffness, alterations in sensation(s), visual problems, difficulties 
with co-ordination, bladder and bowel difficulties, sexual dysfunction, and cognitive 
changes2. One of the most common complaints is fatigue, with studies indicating that 
fatigue is experienced by 75-95% of people with Multiple Sclerosis3. The Multiple 
Sclerosis Council Clinical Practice Guidelines3 (1998) defines fatigue as: 
 
‘A subjective lack of physical and/or mental energy that is perceived by the individual 
or caregiver to interfere with usual and desired activities’. 
 
The cause of fatigue in Multiple Sclerosis is often characterised into primary and 
secondary disease processes. Primary fatigue refers to changes in the brain which are 
hypothesised to directly cause fatigue such as demyelination and axonal loss, 
functional changes, and immunological factors during an ‘attack’ or relapse4. 
Secondary fatigue however, refers to non-direct processes. For example, fatigue due 
to sleep disturbance, reduced physical activity, depression, pain, medication side 
effects, and psychological processes such as self-efficacy4.  
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Fatigue in Multiple Sclerosis, 1) inhibits sustained physical functioning, 2) is 
exacerbated by heat, 3) impacts upon physical functioning, 4) ‘comes on easily’, 5) 
impacts upon the individuals ability to meet their everyday responsibilities, and 6) 
results in ‘problems’ for the individual on a regular basis5. Research has demonstrated 
that fatigue in Multiple Sclerosis is associated with quality of life; Individuals who 
experience fatigue are more likely to experience depression and to report a lower 
quality of life6, even when levels of depression and disability are controlled for7.  
 
Clinical guidelines for the management of fatigue in adults with Multiple Sclerosis 
include both pharmacological and non-pharmacological intervention8. With regard to 
pharmacological treatment, the National Institute for Clinical Excellence8 (2014) 
recommends the use of Amantadine. A recent meta-analysis included seven 
pharmacological trials (including the use of Amantadine and Modafinil), and reported 
a pooled effect size in treating fatigue to be 0.07 (95% CI, -0.22 - 0.37, p = .63)9. 
Non-pharmacological interventions are also recommended within clinical practice 
guidelines, and include mindfulness based training, Cognitive-Behavioural Therapy, 
and fatigue management8. Aerobic, balance, and stretching exercises may also be 
advised8. Comparable with pharmacological treatments, research reports non-
pharmacological treatments (i.e., exercise and educational interventions) to be more 
effective at treating fatigue9. 
 
Fatigue management interventions have been delivered via individual telephone 
sessions10, group based teleconference11,12, group-format community settings1,13-19, 
and via online groups20. 
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One of the most common non-pharmacological fatigue management treatments 
includes energy effectiveness or energy conservation strategies, defined as: ‘the 
identification and development of activity modifications to reduce fatigue through a 
systematic analysis of daily work, home, and leisure activities in all relevant 
environments’3. Energy conservation strategies may include reorganising the 
individual’s environment, using aids and assistive technologies, revisiting and re-
prioritising activities, asserting one’s own needs with others and re-distributing 
activities and tasks accordingly, altering activities to reduce energy consumption, and 
ensuring adequate rest21.  
 
A meta-analysis published in 2013 found energy conservation treatments were more 
effective than no treatment (i.e., waiting list controls) in reducing the impact of 
fatigue (as assessed via self-report), and in improving quality of life for people with 
Multiple Sclerosis21. Furthermore, immediate benefits of participation in energy 
conservation treatments, including reduced impact of fatigue and an improved quality 
of life, are maintained at 12 months post intervention22. 
 
Engaging in any new behaviours, including energy conservation behaviours, is related 
to cognitive and psychological processes. One of the processes theorised to be 
involved in the initiation and maintenance of new behaviours is self-efficacy. 
Grounded in social-cognitive theory, self-efficacy refers to the degree to which an 
individual believes that they are able to perform a task in order to produce a desired 
outcome23. It determines whether an individual engages in coping behaviours, the 
amount of effort that they will apply, and the length of time that the individual will 
continue to apply this effort when they experience difficulties or problems23. The 
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stronger the individual’s self-efficacy expectation, the more active are their coping 
efforts24. 
 
Self-efficacy has been associated with other treatments in Multiple Sclerosis. For 
example, previous research found that pre-treatment self-efficacy was associated with 
adherence to self-administered intramuscular injections at six-month follow up25, and 
adherence to an exercise programme26. Further research has also found that self-
efficacy is associated with physical activity, i.e., individuals with high self-efficacy 
for exercise are more likely to engage in physical activity27.  
 
Self-efficacy is also an important concept in fatigue management treatments such as 
energy conservation, as an individual can be ‘taught’ self-management strategies, but 
if the individual is unsure about whether they have the ability to perform such 
strategies, then they are unlikely to apply the strategies that they have learnt23. 
Increased self-efficacy following energy conservations treatments therefore may 
account for changes in energy conservation behaviours post intervention18. However, 
no studies to date have systematically reviewed the current evidence base to 
determine whether non-pharmacological interventions based on energy conservation 
strategies increase self-efficacy in people with Multiple Sclerosis.  
 
The aims of this study are two-fold: Firstly, to re-examine the current evidence base 
to determine whether energy conservation strategies reduce negative fatigue outcomes 
(i.e., fatigue impact or severity) in people with Multiple Sclerosis. Secondly, to 
investigate whether interventions, based upon energy conservation principles, increase 
self-efficacy for individuals with Multiple Sclerosis experiencing fatigue. Both aims 
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will be addressed by using meta-analyses to produce an overall effect size for both 
fatigue and self-efficacy following energy conservation treatments.  
 
Methods 
 
Search Strategy 
A systematic search of the literature was conducted in April 2017. The Web of 
Science, PubMed, and PsycInfo databases were searched using the following search 
terms: (“energy manag*” OR “energy conserv*” OR “energy sav*” OR “fatigue 
manag*” OR “managing fatigue”) AND “multiple sclerosis” AND (“self efficacy” 
OR “self-efficacy”). The search was filtered to include English language articles only, 
and restricted to publications post-1950.  An ancestral search was also conducted. 
 
Inclusion and eligibility criteria 
The criteria for inclusion in the meta-analysis included: 
Study design: Experimental, quantitative designs. Qualitative designed studies were 
excluded. 
Participants: Adults (aged ≥18 years) with a diagnosis of Multiple Sclerosis, with no 
restrictions as to gender, diagnostic subtype, or duration of the disease. Studies that 
included other neurological conditions met inclusion criteria if they reported separate 
data for the Multiple Sclerosis sample.    
Intervention: Studies must have included a non-pharmacological intervention based 
upon energy conservation principles. Studies were required to meet the following 
definition of energy conservation strategies as described by the Multiple Sclerosis 
Clinical Council: ‘the identification and development of activity modifications to 
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reduce fatigue through a systematic analysis of daily work, home, and leisure 
activities in all relevant environments’3. Fatigue management interventions based 
upon cognitive behavioural therapy were excluded. Studies including 
pharmacological treatments only were excluded.  
Outcome measures: Studies were required to have used pre- and post- intervention 
measures to assess both fatigue, such as the Fatigue Impact Scale28, and self-efficacy, 
such as the Multiple Sclerosis Self-Efficacy Scale29.   
 
Study selection 
The first author initially screened article abstracts, and articles were excluded if the 
topic was not relevant to the meta-analysis. Full text articles were then assessed for 
eligibility. 
 
Data extraction 
Information detailing the demographics of the sample, the intervention, the control 
condition (if present), and outcome measures were obtained from each of the studies. 
As the length of follow-up varied greatly between studies, we used the data for the 
time period immediately post intervention. To ensure consistency, where data from 
both intention-to-treat (ITT) and compliers analyses were reported, data from the ITT 
analyses were used. Where articles did not report the mean and standard deviation for 
the total Fatigue Impact Scale28, an average score was taken from the three subscales 
and incorporated into the analysis. In instances were the published article did not 
report raw data, the first author was contacted via e-mail to request this information. 
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Measurement of research quality  
The methodological quality of the studies included in the meta-analysis was assessed 
using the Evaluative method for evaluating and determining evidence-based 
practices30, 31. This method has demonstrated good psychometric properties31 and has 
been deemed a suitable instrument for the appraisal of experimental research 
designs32.  
 
Each study was initially reviewed and evaluated against a set of primary quality 
indicators, e.g., description of the independent variable (intervention) provided with 
‘replicable precision’.  Studies were awarded a quality rating of high (H), acceptable 
(A), or unacceptable (U). Secondly, each study was reviewed against a set of 
secondary quality indicators, e.g., treatment fidelity and attrition. These secondary 
quality indicators were rated dichotomously as either the study demonstrated or did 
not demonstrate evidence of each of the indicators. Finally, the overall strength of the 
research article was determined by synthesising the ratings from the appraisal of both 
the primary and secondary quality indicators. Each study was awarded an overall 
strength of strong (S), adequate (A), or weak (W).  
 
Data analysis 
The Metafor package33 for R34 was used to conduct all statistical analyses. Initially, 
the effect size for each study was calculated using the mean and standard deviation. 
For studies that reported the mean and standard error only, the standard error was 
transformed into the standard deviation using the equation: SD = SE X (√ n), allowing 
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for an effect size to be calculated. Where no raw data was available, the effect size 
stated in the article was added to the model in Metafor.  
 
Once an effect size had been calculated for each study, an overall effect size was 
calculated using a random-effects model. Using Cohen’s (1988)35 guidelines, effect 
sizes were interpreted as either small (r = 0.10), medium (r = 0.30), or large (r = 
0.50). 
Results 
 
Included studies 
Of the initial 75 articles identified, the first author reviewed the article’s title and 
abstract to determine whether the criteria for inclusion were met. Ten articles were 
removed at this stage, as the topic was not relevant to the meta-analysis. Sixty-five 
full text-articles were then reviewed, and 10 were assessed as meeting the criteria for 
inclusion in the meta-analysis. One article did not provide either the raw data or effect 
sizes, and these were unable to be obtained from the corresponding author of the 
study. This article was therefore excluded.  Figure 1. provides a diagrammatic 
summary of the study selection process.  
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Figure 1. PRISMA (2009) flow diagram of the literature search process 
 
A total of nine studies (n = 587) published between 2001 and 2016 were identified as 
meeting the criteria for inclusion in the meta-analysis. Three studies employed a 
single group design11,17,18, and five studies were randomised controlled trials (RCT)13-
16,19,36. One article, Lamb et al. (2007)36, was a secondary data analysis from a 
previous RCT. Six studies included a comparison condition, these ranged from 
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waiting list control14 and delayed treatment control15, to peer support groups 13,18, 
current local practice19, and a placebo intervention which included the provision of 
general information such as car adaptations16. For five studies11,13,15,18,36, the original 
or a modified version of the “Managing Fatigue” energy conservation course 
developed by Packer et al. (1995)37 was administered during the intervention phase. 
This was the most common treatment approach.  
 
Outcome measures. The most commonly used measure of fatigue was the Fatigue 
Impact Scale28 (n = 6/9 studies, 67%), followed by the Modified Fatigue Impact 
Scale3 (n = 2/9, 22%), and the Global Fatigue Severity subscale of the Fatigue 
Assessment Instrument38 (n = 1/9, 11%). Where both the impact and severity of 
fatigue were measured, data from the Fatigue Impact Scale28 or the Modified Fatigue 
Impact Scale3 were used in an attempt to maintain consistency across studies.  
 
Self-efficacy was assessed using four different measures. The Multiple Sclerosis Self-
Efficacy Scale29 (n = 4/9 studies, 45%) and the Self-Efficacy for Performing Energy 
Conservation Strategies Scale39 (n=3/9, 33%) were the most commonly used. Other 
measures included the Self-efficacy Gauge40 (n = 1/9, 11%) and the Multiple 
Sclerosis Fatigue Self Efficacy Scale41  (n = 1/9, 11%).  
 
Table 1. provides a summary description of the studies included in the meta-analysis.
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Table 1. Summary descriptions of the studies included in the meta-analysis 
 
First 
Author 
(Year) 
Design n Follow-
up 
Age 
 
Gender Intervention Control Outcomes  
(Pre-Post) 
Research 
Report 
Strength 
Finlayson 
(2005)11 
 
 
Single 
group 
 
 
 
29 
 
 
 
0 
 
 
 
 
 
 
47 (9.6) 
 
 
5m, 24f 
 
 
 
 
Modified 
“Managing Fatigue” 
by Packer (delivered 
via teleconference) 
- 
 
 
 
 
 
 
SEQ: 7.46(1.11) – 7.81 (1.37) 
FIS Total: 124.83 (27.1) – 112.1 (29.78) 
 
W 
 
 
García 
Jalón 
(2012)13 
 
RCT E: 13 
C: 10 
3m E: 45.9 (9.9) 
C: 52 (7) 
E: 3m, 10f 
C: 4m, 6f 
Energy conservation 
programme by 
Packer 
 
Peer support 
group 
 
Energy conservation group: 
MSSS: 46(8.5) - 43.31(8.74) 
FIS: 83.31(16.26) - 59.62(23.14) 
Support Group: 
MSSS: 49.9(7.5) - 43.5(8.44) 
FIS: 80.9(21.73) - 63.3(26.03) 
A 
Hugos 
(2010)14 
 
RCT E: 15 
C: 15 
13w E: 58.4 (7.7) 
C: 55.4 (9.1) 
E: 4m, 11f 
C: 2m, 13f 
“Take control” 
programme 
 
Wait-list 
control 
Week 1 to Week 5+ 
‘Take control’ group: 
MSSS:1362.67(61.3) - 1391(61.3) 
MFIS: 44(3.46) - 39.79(6.44) 
Wait-list control group: 
MSSS:1284.67(61.3)- 1318.57(63.45) 
MFIS: 44.4(3.35) - 40.43(3.46) 
A 
Kos 
(2007)16 
 
RCT E: 28 
C: 23 
6m E: 42.9 (9.1) 
C: 44.5 (9.9) 
E: 8m, 20f 
C: 8m, 15f 
Multi-disciplinary 
fatigue management 
programme 
 
Placebo 
intervention 
Baseline to Week 35 (ITT group) 
Fatigue management: 
MFIS: 46.69(10.80) - 42.03(11.96) 
MSSS (function subscale): 
A 
23 
694.31(155.37) - 689.4(135.95) 
MSSS (control subscale): 
516.08(185.18) - 577.57(165.98) 
Lamb 
(2005)36 
 
RCT 43 0 48.4 (10) 7m, 36f “Managing fatigue” 
programme by 
Packer 
- FIS: 115.2(28.4) - 102.86(30.06) 
SEPECSA: 7(2.06) - 8.11(1.27) 
A 
Mathiowetz 
(2005)15 
 
 
RCT 
 
169 6w 
 
48.34 (8.44) 29m, 140f Energy conservation 
course by Packer 
 
Delayed 
treatment 
control 
(ITT LOCF Effect size) 
FIS Cognitive subscale: 0.52 
FIS Physical subscale: 0.74 
FIS Social subscale: 0.69 
SEPECSA: 1.82 
S 
Mathiowetz 
(2001)18 
 
Single 
group 
54 6w 50 (31-74#) 18m, 36f Energy conservation 
course by Packer 
 
Support 
group 
Energy conservation (week 7-13): 
FIS: 66.4(26.5) - 55.8(29.7) 
SEG: 206.1(40.4) - 214(35.8) 
Support group (week 1-7): 
FIS: 68.9(26.2) - 66.4(26.5) 
SEG: 201.5(36.3) - 206.1(40.4) 
A 
Mulligan 
(2016)17 
 
Single 
group 
24 0 49.29 (8.12) 0m, 24f “Minimise Fatigue, 
Maximise Life: 
Creating balance 
with Multiple 
Sclerosis” (MFML) 
- Time 2 - Time 3: 
MFIS: 11.25(4.12) - 9.17(3.57) 
MSSS: 34.75(12.79) - 43.3(11.85) 
W 
Thomas 
(2013)19 
 
RCT E: 84 
C: 80 
4m E: 48.0 (10.2) 
C: 50.1 (9.1) 
E: 23m, 61f 
C: 22m, 58f 
“Fatigue: Applying 
cognitive 
behavioural and 
energy effectiveness 
techniques to 
lifestyle (FACETS)” 
 
Current 
local 
practice 
(CLP) 
FACETS group: 
GFS: 5.6(.98) - 5.48(.92) 
MSFSE: 45(17) - 57(17) 
CLP group: 
GFS: 5.61(1.09) - 5.55(1.17) 
MSFSE: 49(16) - 50(17) 
S 
24 
 
 
 
 
 
 
 
 
 
 
 
 
Note. All values are M (SD) unless otherwise stated, + = Values in brackets are standard error, # = range. 
Abbreviations: A, adequate; C, control group; E, experimental group; f, female; FIS, Fatigue Impact Scale; GFS, Global Fatigue Severity subscale of the Fatigue 
Assessment Inventory; m, male; MFIS, Modified Fatigue Impact Scale; MSFSES, MS Fatigue Self-efficacy Scale; MSSS, MS Self-efficacy Scale; RCT, Randomised 
Controlled Trial; S, Strong; SEG, Self-efficacy gauge; SEPECSA, Self-efficacy for performing energy conservation strategies assessment; SEQ, Self-efficacy 
Questionnaire; W, Weak. 
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Data extraction 
One study, by Mathiowetz et al. (2005)15 reported ITT data using both the method of 
last-observation-carried-forward (LOCF) and using the maximum likelihood method. 
In this case, data from the LOCF method was used. 
 
Measurement of research quality  
Using the Evaluative method30,31, two studies were assessed to be of weak quality, 
five were of adequate quality, and two studies were of strong quality. The research 
report strength for each study is detailed in Table 1.   
 
Publication bias 
Although it was not possible to thoroughly assess for publication bias due to the 
limited number of studies included in the analysis, a visual review of the funnel plots 
did not reveal any obvious positive bias (see appendix). 
 
Effectiveness of energy conservation treatments  
Effect sizes for fatigue outcomes post-intervention ranged from -0.01 to -0.65. The 
pooled effect size was -0.39 (95% CI, -0.54 to -0.25, p = .001), which equates to a 
medium effect size. The test for heterogeneity was significant (Q = 24.09, p < .01, I2 = 
62.25%). Figure 2. demonstrates the effect size for each individual study and the 
overall effect size for fatigue. 
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Figure 2. Forest plot for fatigue outcomes. 
 
Self-efficacy 
Effect sizes for self-efficacy outcomes post-intervention ranged from -0.02 to 1.82. 
The pooled effect size was 0.53 (95% CI, 0.15 to 0.9, p = .01), equating to a large 
effect size. The test for heterogeneity was significant (Q = 347.61, p <. 01, I2 = 
95.41%). Figure 3. details the effect size for each study and the overall effect size for 
self-efficacy. 
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Figure 3. Forest plot for self-efficacy outcomes. 
 
Discussion 
 
The aim of this study was to systematically review the effectiveness of energy 
conservation interventions in reducing fatigue and increasing self-efficacy in people 
with Multiple Sclerosis, and to use meta-analysis to produce an overall effect size for 
both fatigue and self-efficacy. 
 
Effectiveness on fatigue 
With regard to fatigue, the meta-analysis revealed that fatigue management 
interventions which incorporate energy conservation strategies, are moderately 
effective at reducing the impact or severity of fatigue when compared to no treatment 
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(i.e., wait-list control), a placebo intervention, or alternative support. These findings 
support previous research that also reported energy conservation strategies to be 
effective at reducing fatigue 21.  
 
Effectiveness on Self-Efficacy 
The main aim of this study however was to determine whether energy conservation 
strategies are effective at enhancing self-efficacy in people with Multiple Sclerosis 
experiencing fatigue. Results from the meta-analysis showed that energy conservation 
interventions do increase self-efficacy, with a large effect.  
 
The current literature base suggests that self-efficacy is an important psychological 
construct in Multiple Sclerosis. Although self-efficacy is unlikely to be the sole 
determinant of engagement in energy conservation strategies, it is highly likely to 
influence the initiation of such behaviours, and the quantity of both time and effort an 
individual will expend in these behaviours23. Interventions that increase self-efficacy 
may therefore increase the likelihood than an individual will utilise energy 
conservation strategies. Furthermore, an increased self-efficacy for fatigue 
management may generalise to other behaviours that were previously limited due to 
the individual’s lack of efficacy expectations23. Fatigue management strategies that 
increase self-efficacy may therefore have positive consequences on other health 
outcomes in addition to reducing the impact of fatigue.  
 
Study limitations 
This meta-analysis included a relatively small sample of 9 studies, including 587 
people with Multiple Sclerosis, and therefore the findings should be interpreted with 
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some caution. There was also some variation in the methodological quality of the 
studies included in this meta-analysis. Whilst, the majority of studies were assessed as 
being of adequate or strong quality, some studies were of weak methodological 
quality. This was typically due to the lack of an appropriate control condition. Some 
caution may be required in interpreting the findings of this study due to the overall 
quality of the studies included in the meta-analysis. The literature base would 
therefore also benefit from future high quality randomised controlled clinical trials.  
 
In this study, the effectiveness of energy conservation strategies in reducing fatigue 
and increasing self-efficacy was assessed using data collected immediately post-
intervention. The findings from this paper therefore are limited to the short-term 
effects of energy conservation interventions, and it is not possible to conclude 
whether these findings would be maintained over time. Although, previous studies 
have found a reduction in fatigue, following participation in energy conservation 
treatments, to be maintained one year post-intervention22. It is possible that reductions 
in fatigue impact may be due to a sustained increase in self-efficacy for performing 
energy conservation strategies; however further research is required to investigate this 
hypothesis.  
 
Future research 
This study found energy conservation interventions reduce fatigue impact and 
increase self-efficacy. However, it is not clear as to the relationship between these two 
variables. Future research may wish to incorporate a meditational analysis to 
determine whether the increase in self-efficacy indirectly accounts for the reduction in 
fatigue impact, by increasing the uptake of energy conservation strategies.   
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This meta-analysis incorporated studies in which energy conservation interventions 
were delivered via a number of different modalities including community groups and 
teleconference. In addition, there was some variation in the fatigue management 
approaches used, including programmes based on Packer37 and the group-based 
fatigue management programme (FACETS).  In this study, the test for heterogeneity 
was significant for fatigue and self-efficacy outcomes, indicating varying 
effectiveness across studies.  This may be due to differences in treatment modality, 
treatment approaches, or other variables. Therefore an interesting focus of future 
research may be in examining what variables account for differences in effectiveness. 
This may guide future service development and clinical work to ensure people with 
Multiple Sclerosis experiencing fatigue are offered the most effective treatment.   
 
Finally, the number of studies included in the meta-analysis was limited, as some 
studies examining the effectiveness of energy conservation treatments did not include 
a measure of self-efficacy. Future research studies should therefore incorporate a 
measure of self-efficacy. 
Conclusions 
 
This study is the first to systematically review the literature and to use meta-analysis 
to determine whether energy conservations interventions increase self-efficacy in 
people with Multiple Sclerosis. The results suggest that energy conservations 
interventions may be more effective than either no treatment or general support in 
increasing self-efficacy in the short-term. Future research may wish to consider 
whether the increase in self-efficacy is maintained over time.  
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Abstract  
 
Objective: To investigate whether self-efficacy remains predictive of perceived cognitive 
impairment after controlling for objective cognitive functioning, and to further examine 
the relationship between self-efficacy and cognitive domains, as measured objectively.  
Design: A cross-sectional design was employed. 
Setting: General community setting within a semi-rural part of the United Kingdom.  
Participants: A convenience sample of twenty-five participants with a diagnosis of 
Multiple Sclerosis. Participants were recruited via National Health Service clinics and the 
Multiple Sclerosis Society.  Eligible participants were those with a diagnosis of Multiple 
Sclerosis (any subtype), aged ≥ 18 years, of fluent English language, and with sufficient 
cognitive and motor ability to complete neuropsychological assessment. 
Intervention(s): Not applicable. 
Main Outcome Measure(s): The main outcome measures included the Liverpool Self-
efficacy Scale1 as a measure of self-efficacy, and the Cognitive Function (v.2) 
questionnaire of the Quality of Life in Neurological Disorders (Neuro-QOL) Measures2 
to assess perceived cognitive impairment. Objective cognitive functioning, i.e., attention, 
processing speed, memory, and executive functioning, was assessed using a variety of 
neuropsychological measures. 
Results: Using regression analyses, self-efficacy was found to significantly predict 
perceived cognitive impairment, even after controlling for objective cognitive 
functioning. Self-efficacy accounted for 45% of the variance in perceived cognitive 
impairment (F(1,22 = 8.92, p = .001). Correlational analyses revealed a significant 
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relationship between self-efficacy and processing speed, and self-efficacy and executive 
function. 
Conclusion(s): Self-efficacy is associated with the perception of cognitive impairment in 
people with Multiple Sclerosis, and therefore may be an important aspect of self-
management programmes.   
Key words: Self-efficacy, cognition, Multiple Sclerosis. 
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Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system causing 
inflammation, demyelination and axonal loss within the brain and spinal cord3. A review 
of the General Practice Research Database estimated the prevalence of MS in the U.K to 
be 203.4 per 100,000 population in 2010, with women accounting for 72% of the 
prevalence rates4. Clinical symptoms vary dependent upon the lesion site affected, and 
the subsequent disease course of either relapsing-remitting or progressive MS. However, 
symptoms can include motor, cognitive, and behavioural deficits5, and neuropsychiatric 
complications such as depression and anxiety6.  
 
The research literature refers to a number of different psychological processes that may 
impact upon an individual’s ability to adjust to life with a physical health condition, such 
as MS7. One of these psychological processes, grounded in social-cognitive theory, is 
self-efficacy. Differentiated from outcome expectancies, i.e., the understanding that 
performing a behaviour will lead to a specific outcome8, self-efficacy expectations refers 
to the degree to which an individual believes that they are able to perform a task in order 
to produce a desired outcome9.  Self-efficacy is one of the major determinants of peoples 
choice of activities, how much effort they expend in a task, and how long they persist in 
the face of difficulties9,10. Yet, possibly due to the unpredictable nature of the disease, 
people with MS experience lower levels of self-efficacy than people with other physical 
health conditions, including spinal cord injury11. 
 
Research suggests that self-efficacy is associated with health-related quality of life, 
depression, and social functioning12, as well as physical activity in people with MS13. 
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However, only three studies to date have investigated the relationship between self-
efficacy and cognition in people with MS. Initial research examined self-efficacy in the 
context of perceived cognitive impairment i.e., impairment as measured by patient self-
report. Research by Schmitt and colleagues in 2014 found self-efficacy to be predictive of 
perceived cognitive impairment in a sample of individuals with a range diagnostic 
subtypes12. Expanding these initial findings, longitudinal research found self-efficacy to 
remain predictive of perceived cognitive impairment over a three-year period14. Although 
depression and fatigue are associated with perceived cognitive impairment in MS15, self-
efficacy continues to be predictive of perceived cognitive impairment even when these 
variables are controlled for14. 
 
More recent research has begun to consider the relationship between self-efficacy and 
objective cognitive functioning, i.e., cognitive ability as measured using computer or 
clinician administered neuropsychological assessments. Using a sample of participants 
with clinically isolated syndrome or early relapsing-remitting MS, Jongen and colleagues 
(2015) found self-efficacy to be associated with power of attention, reaction time 
variability, and speed of memory, using a computerised battery of cognitive tests16. The 
findings suggest that self-efficacy positively affects performance on cognitive tests, 
particularly in the cognitive domains most typically affected by MS16.  The authors also 
hypothesised that cognitive ability may impact upon self-efficacy, in that individuals with 
greater cognitive capacity may feel better able to manage their symptoms as compared to 
individuals with impaired cognition16.  
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Cognitive impairments are reported to occur in approximately 45-65% of people with 
MS, and commonly include deficits in attention, memory, and executive functioning17. 
The impact of cognitive impairment is wide spread, and includes a greater risk of 
unemployment, reduced engagement in social activities, and increased difficulties 
undertaking activities of everyday living18. Therefore, understanding psychological 
variables associated with cognition is essential in order to continue to develop self-
management interventions that are grounded in the evidence base.  
 
The primary aim of this study was to address the current gaps in the research literature by 
investigating whether self-efficacy remains predictive of perceived cognitive impairment, 
even when objective cognitive functioning has been controlled for. Secondly, this study 
aimed to add to the currently limited literature base by examining the relationship 
between self-efficacy and objective cognitive functioning using ecologically valid 
measurement tools. 
 
Methods 
 
Participants  
The participant sample (n = 25) was recruited from National Health Service clinics and 
from local branches of the MS Society, based within a semi-rural area in North Wales, 
United Kingdom. Eligible participants were those with a diagnosis of MS, aged ≥ 18 
years, of fluent English language, and with sufficient cognitive and motor ability to 
complete neuropsychological assessment. Exclusion criteria included co-morbid 
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neurological diagnoses (including diagnosis of a dementia syndrome), current substance 
misuse, and significant current mental health difficulties that would impact upon capacity 
to provide informed consent.  
 
Measures 
Clinical Measures. Participants completed five questionnaire measures. 
Self-efficacy. Self-efficacy was measured using the Liverpool Self-efficacy Scale1. This is 
an 11-item Likert-type scale, consisting of two domains of control and personal agency. 
The scale has been validated using a sample of people with MS; the authors report good 
internal consistency (α = 0.81) and acceptable test-retest reliability (intraclass correlation 
coefficient of 0.79)1. Low scores on this scale are associated with low self-efficacy.   
Perceived cognitive impairment. The Cognitive Function questionnaire of the Quality of 
Life in Neurological Disorders2 (Neuro-QOL) short-form measure (version 2) assesses 
both executive function and general concerns (e.g., attention, memory, planning, and 
organising), and consists of 8 items scored on a 5-point Likert scale. This short-form 
measure allows for raw scores to be converted into standardised T scores (M = 50, SD = 
10). Higher scores denote less perceived cognitive difficulty.  
Multiple Sclerosis subtype and neurological impairment. MS subtype was assessed using 
self-report. Where participants were unsure as to their diagnosis, their MS specialist nurse 
was consulted (with written consent) to obtain this information. Neurological impairment 
was assessed using the Multiple Sclerosis Questionnaire19. This 17-item questionnaire 
has been demonstrated to be highly cross-correlated with other measures of impairment 
in MS and is therefore recommended as a valid and accurate measure19.  
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Fatigue. The Patient-Reported Outcomes Measurement Information System (PROMIS) 
Fatigue short form for MS was administered to assess fatigue20. This measure includes 8 
items scored using a 5-point Likert scale. Raw scores are converted to standardised T 
scores (M = 50, SD = 10). The PROMIS measures have been shown to be valid for use 
with people with MS21. Higher scores on this measure are associated with greater levels 
of fatigue.  
Depression. Symptoms associated with depression were assessed using the Patient Health 
Questionnaire (PHQ-9)22. This 9-item measure is scored using a 4-point Likert-type 
scale. The PHQ-9 has been validated for use in a MS sample23. Higher scores are 
associated with greater symptoms of depression.  
 
Neuropsychological measures. Participants completed a series of neuropsychological 
assessments, covering a breadth of cognitive domains. 
Attention. The Paced Auditory Serial Additions Test (PASAT)24 was initially developed 
as a measure of information processing speed and flexibility. It has since been adapted25, 
and subsequently has been extensively used within the MS population as a measure of 
attention. Participants are presented with a series of single-digit numbers using a pre-
recorded tape, and are required to add the most recent number to the one presented 
immediately before it. Participants are not required to keep a running total, but to provide 
the sum of the last two numbers heard. There are two subtests, and the numbers are 
presented at a rate of every three seconds on the first subtest and every two seconds on 
the following subtest. On each subtest, participants are presented with a total of 60 
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numbers.  The PASAT has demonstrated good internal consistency26. High scores 
represent greater attentional abilities.  
Processing Speed. The symbol search and coding subtests of the Wechsler Adult 
Intelligence Scale fourth edition (WAIS-IV)26 were administered as a measure of speed 
of information processing. The symbol search subtest assesses both processing speed and 
visual perception. On the symbol search subtest, participants are required to scan a series 
of symbols presented sequentially in a row, and identify whether they match a target 
symbol. On the coding subtest, participants are required to translate symbols, each 
uniquely associated with a number, into boxes. Both the symbol search and coding 
subtests are timed tasks of two minutes each, and therefore participants are encouraged to 
work as quickly and accurately as possible. Scores on the symbol search and coding 
subtests are converted into a processing speed index score (M = 100, SD = 15). Higher 
scores reflect a quicker processing speed.  
Memory. The Logical Memory subtests of the Wechsler Memory Scale fourth edition 
(WMS-IV)28 were administered as a measure of immediate and delayed verbal memory. 
The researcher read two short stories, which participants were required to recall both 
immediately and after a 30-minute delay. There are two versions available, one for adults 
(16-69 years) and one for older adults (aged 65-90 years). These were administered 
accordingly given the participant’s age. Higher scores indicate greater recall.  
Executive Function. Executive functioning was measured using the 6 Elements Test of 
the Behavioural Assessment of the Dysexecutive Syndrome (BADS)29. This is a set task 
of ten minutes in which participants are instructed to undertake three different types of 
tasks, a dictation task, a picture-naming task, and an arithmetic task. Participants are 
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advised to adhere to specific rules throughout the task, with points deducted if the rules 
are not observed. Low scores represent executive dysfunction.  
 
Procedure 
Ethical approval was obtained from the School of Psychology, Bangor University, and 
from the Research and Ethics Committee of local Health Board. Participants were 
recruited via three methods: Potential participants who met the eligibility criteria were 
approached during their routine National Health Service (NHS) MS nurse appointment, 
and the third author approached potential participants at their NHS clinical psychology 
appointment. The first author also contacted the local branches of the MS Society and 
presented details about the research study at Society meetings. Potential participants were 
provided with a bilingual (English and Welsh) information pack, containing an 
information sheet and an initial contact form. Interested participants were advised to 
return the initial contact form to the first author using a freepost envelope provided in the 
information pack. Upon receipt of the initial contact form, participants were contacted via 
telephone and a research appointment was arranged. Appointments took place within 
NHS premises or within the participants’ own home. Written consent was obtained at the 
start of the appointment, and subsequently, the questionnaire and neuropsychological 
measures were administered. Measures were completed over 1-3 appointments as 
requested by the research participant to accommodate for participant fatigue. Recruitment 
and testing took place between September 2016 and March 2017.  
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Data analyses  
The Statistical Package for the Social Sciences (SPSS) version 23 was used to perform all 
analyses. In order to create a single measure of objective cognitive functioning, tests 
measuring the four individual cognitive domains (i.e., attention, processing speed, 
memory, executive function) were standardised and averaged, before the four cognitive 
domain scores were averaged to create a single measure. Specifically, the raw scores for 
each neuropsychological assessment were converted into standardised scores using 
normative data. The WMS-IV Logical Memory subtest raw scores were converted into 
scaled scores using normative data based upon age (M = 10, SD = 3). These two scaled 
scores were each transformed into z scores. An average of the two z scores was then 
calculated to produce an overall z score for verbal memory. For the WAIS-IV symbol 
search and coding subtests, again, each raw score was converted into a scaled score using 
normative data based upon age (M = 10, SD = 3). The sum of the two scaled scores were 
then transformed into a processing speed composite score (M = 100, SD = 15). A final z 
score for processing speed was then calculated from the composite score.  Scores on the 
PASAT and the BADS 6 Elements Test were converted into z scores to generate a total 
score for attention and executive functioning respectively. Finally, the z scores for each 
cognitive domain were averaged, using the mean, to create a unified measure of objective 
cognitive functioning (M = 0, SD = 1). 
 
The primary aim of this study was to determine whether self-efficacy remains predictive 
of perceived cognitive impairment, even when objective cognitive functioning has been 
controlled for. This aim was addressed using hierarchical regression analyses, with 
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perceived cognitive impairment as the outcome variable, and objective cognitive 
functioning and self-efficacy as the predictor variables. Objective cognitive functioning 
was entered into the regression model at stage 1 (Model 1), and self-efficacy was entered 
into the model at stage 2 (Model 2). This study also aimed to further examine the 
relationship between self-efficacy and objective cognitive functioning. Therefore 
correlational analyses were performed between self-efficacy and the cognitive domains of 
attention, processing speed, memory, and executive functioning. The data were initially 
examined to determine whether the assumptions for parametric analyses were met, and 
either Pearson’s product or Spearman’s rho analyses were performed, dependent upon 
whether the data were normally distributed.  
 
Results 
 
Participants 
Descriptive statistics for demographic variables, self-efficacy, fatigue, perceived 
cognitive impairment, and depression are presented in Table 1. The majority of 
participants were female (n = 18), and all participants were aged between 31 and 78 (M = 
52.92, SD = 12.96). Ten participants had a diagnosis of relapsing-remitting MS (40%), 
nine participants had a diagnosis of secondary progressive MS (36%), and six 
participants had a diagnosis of primary progressive MS (24%). Participants had 
experienced symptoms of MS for between 33 and 480 months (M = 185.68, SD = 
111.28), and had received a diagnosis of MS between 22 and 300 months prior to 
undertaking the research project (M = 132.16, SD = 91.30).  
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Table 1. 
Descriptive statistics for demographic and disease-related variables, fatigue, depression, 
self-efficacy, and perceived cognitive impairment 
 
Details regarding neurological impairment for the sample are provided in Table 2. Based 
upon the mean score on the PHQ-9, the sample was experiencing a mild to moderate 
level of depression. Perceived cognitive impairment and fatigue fell within one standard 
deviation of the population mean. Group means and standard deviations for performance 
on neuropsychological assessments are displayed in the appendix.   
 
 
 
 Values (n = 25) 
Education level  
School or less 8 (32) 
College course or equivalent 7 (28) 
University degree or higher 10 (40) 
Employment Status  
Employed full time 7 (28) 
Unemployed 3 (12) 
Retired/retired on ill-health grounds 15 (60) 
Ethnicity  
White British 21 (84) 
Welsh 1 (4) 
Other ethnicity  3 (12) 
PROMIS-Fatigue 58.85 ± 10.52 (34.7, 81.3) 
PHQ-9 9.6 ± 7.14 (0, 26) 
Liverpool Self-efficacy Scale   
Control subscale 15.76 ± 4.42 (7, 24) 
Personal agency subscale 13 ± 3.01 (6, 20) 
Total score 28.76 ± 6.95 (14, 44) 
NeuroQOL-Cognitive Function 42.72 ± 7.72 (25.9, 56.3) 
Note. Values are mean ± SD (minimum, maximum) or n (%). 
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Table 2. 
Neurological impairment (MS Questionnaire19)  
 
Regression analysis 
A hierarchical regression analysis revealed that objective cognitive functioning only 
explained 12% of the variance in perceived cognitive impairment, and this model (Model 
1) was not significantly better than chance (F(1,23) = 3.15, p = .089). When both objective 
cognitive functioning and self-efficacy were entered at stage 2 (Model 2), they explained 
45% of the variance and significantly contributed to the model (F(1,22) = 8.92, p =.001). 
The regression analysis is detailed in Table 3.   
 
 
                                                                                      (%) 
Require an aid to walk 48 
Uses a wheelchair for almost all activities 16 
Mild weakness 12 
Moderate or severe weakness 64 
Mildly impaired sensation 28 
Moderately or severely impaired sensation 56 
Mildly impaired visual acuity 4 
Moderately or severely impaired visual acuity 12 
Mildly uncoordinated 32 
Moderately or severely uncoordinated 24 
Mild difficulties with speech 12 
Moderate or severe difficulties with speech 12 
Mild difficulty with balance 16 
Moderate or severe difficulty with balance 68 
Mild spasticity and/or spasms 40 
Moderate or severe spasticity and/or spasms 48 
Mild difficulty with swallowing 32 
Moderate or severe difficulty with swallowing 4 
Difficulties with bowel or bladder function 76 
Mild dizziness or vertigo 32 
Moderate to severe dizziness or vertigo 12 
 60 
Table 3. 
Regression analyses 
 Model 1 Model 2 
Variable B SE B β B SE B β 
Constant  44.46 1.78 - 19.90 6.95 - 
OCF 2.67 1.50 .35 -0.48 1.49 -.06 
Self-efficacy - - - 0.78 0.22 .70** 
Adjusted R2 - .08 - - .40 - 
R2 Change - .12 - - .33 - 
F Change - 3.15 - - 13.05 - 
Note. OCF, objective cognitive functioning; **p = .002 
 
Correlational analyses 
Correlational analysis between self-efficacy and cognitive domains 
A significant relationship between self-efficacy and processing speed was found on both 
the personal agency subscale and the total self-efficacy score. A significant relationship 
between executive function and both the control subscale and self-efficacy total score 
was also found. No other significant relationships were found between self-efficacy and 
cognitive domains. All correlational analyses are demonstrated in Table 4. 
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Table 4. 
Correlational analyses between self-efficacy and cognitive domains 
                          Cognitive Domain 
 Attention Processing Speeda Memory Executive Function 
Control .11 .33 .31 .49* 
Personal agency .31 .51** .34 .26 
Total self-efficacy 
 
.15 .43* .33 
 
.42* 
Note. **p<. 01, *p<. 05 (2-tailed) 
All values are Spearman’s rho, unless otherwise stated 
a =Pearson’s r 
 
Discussion 
 
Extending previous research 12,14,, this study found self-efficacy significantly predicts 
perceived cognitive impairment in individuals MS, even when controlling for objective 
cognitive functioning. In this sample, objective cognitive functioning was not a 
significant predictor of perceived cognitive impairment. This may be due to discrepancy 
between perceived and objective cognitive impairment found in individuals with MS30.  
The relationship between self-efficacy and specific cognitive domains was also 
investigated. Unlike previous research by Jongen and colleague (2015)16, there was not a 
significant relationship between attention and self-efficacy, although this may be due to 
differences in measurement. However, this study found a significant relationship between 
processing speed and self-efficacy, and executive functioning and self-efficacy. One of 
the strengths of this study was the use of ecologically valid measures of objective 
cognitive functioning. Furthermore, this study adds to the current literature on self-
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efficacy and objective cognitive functioning by including people with a wider variety of 
diagnostic subtypes. 
 
The findings from this study have both clinical and research implications. With regard to 
research implications, this study was the first to examine whether self-efficacy remains 
predictive of perceived cognitive impairment, whilst controlling for objective cognitive 
functioning. This study may therefore benefit from replication to ensure the findings are 
robust. With regard to clinical practice, clinicians may wish to consider whether self-
management interventions, aimed at enhancing self-efficacy, reduce perceived cognitive 
impairment. Such studies would need to be carefully evaluated to determine their 
effectiveness. However, this is a meaningful area of rehabilitative work that has the 
potential to improve health outcomes for people with MS.  
 
Study limitations 
Previous research has found perceived cognitive impairment to be associated with 
depression and fatigue in individuals with MS15. However, due to the relatively small 
sample size and therefore limited statistical power of this study, depression and fatigue 
were not entered into the regression analysis. In addition, no demographic or disease-
related variables were entered in to the regression model. However, previous research has 
not found a relationship between demographic variables (including age and diagnostic 
subtype) and self-efficacy in a sample of people with MS1. It is therefore possible that 
these variables would not have significantly contributed to the regression model. 
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Due to the cross-sectional design of this study, it is not possible to infer the direction of 
causality between self-efficacy and perceived cognitive impairment. Indeed, some 
authors have proposed that cognitive ability may affect self-efficacy, as opposed to self-
efficacy affecting cognition16. Longitudinal research would be required to address this 
question. This study also assessed self-efficacy for MS in terms of sense of control and 
personal agency, as opposed to self-efficacy specifically in regard to cognition. However, 
participants were aware that they had consented to take part in a study on self-efficacy 
and cognition, and so it is reasonable to infer that they completed the self-efficacy 
measure with cognition in mind. Finally, due to the relatively small sample size included 
in this study, one should interpret the findings with some cautiousness.  
 
Conclusion 
 
The present study was the first to examine the role of objective cognitive functioning in 
the relationship between self-efficacy and perceived cognitive impairment in people with 
MS. This study found that self-efficacy was predictive of perceived cognitive 
impairment, and remained so after controlling for objective cognitive functioning. There 
was a significant relationship between processing speed and self-efficacy, and executive 
functioning and self-efficacy; this study did not find a significant relationship between 
attention and self-efficacy, or verbal memory and self-efficacy. 
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Abstract  
 
Objective: To investigate whether self-efficacy remains predictive of perceived cognitive 
impairment after controlling for objective cognitive functioning, and to further examine 
the relationship between self-efficacy and cognitive domains, as measured objectively.  
Design: A cross-sectional design was employed. 
Setting: General community setting within a semi-rural part of the United Kingdom.  
Participants: A convenience sample of twenty-five participants with a diagnosis of 
Multiple Sclerosis. Participants were recruited via National Health Service clinics and the 
Multiple Sclerosis Society.  Eligible participants were those with a diagnosis of Multiple 
Sclerosis (any subtype), aged ≥ 18 years, of fluent English language, and with sufficient 
cognitive and motor ability to complete neuropsychological assessment. 
Intervention(s): Not applicable. 
Main Outcome Measure(s): The main outcome measures included the Liverpool Self-
efficacy Scale1 as a measure of self-efficacy, and the Cognitive Function (v.2) 
questionnaire of the Quality of Life in Neurological Disorders (Neuro-QOL) Measures2 
to assess perceived cognitive impairment. Objective cognitive functioning, i.e., attention, 
processing speed, memory, and executive functioning, was assessed using a variety of 
neuropsychological measures. 
Results: Using regression analyses, self-efficacy was found to significantly predict 
perceived cognitive impairment, even after controlling for objective cognitive 
functioning. Self-efficacy accounted for 45% of the variance in perceived cognitive 
impairment (F(1,22 = 8.92, p = .001). Correlational analyses revealed a significant 
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relationship between self-efficacy and processing speed, and self-efficacy and executive 
function. 
Conclusion(s): Self-efficacy is associated with the perception of cognitive impairment in 
people with Multiple Sclerosis, and therefore may be an important aspect of self-
management programmes.   
Key words: Self-efficacy, cognition, Multiple Sclerosis. 
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Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system causing 
inflammation, demyelination and axonal loss within the brain and spinal cord3. A review 
of the General Practice Research Database estimated the prevalence of MS in the U.K to 
be 203.4 per 100,000 population in 2010, with women accounting for 72% of the 
prevalence rates4. Clinical symptoms vary dependent upon the lesion site affected, and 
the subsequent disease course of either relapsing-remitting or progressive MS. However, 
symptoms can include motor, cognitive, and behavioural deficits5, and neuropsychiatric 
complications such as depression and anxiety6.  
 
The research literature refers to a number of different psychological processes that may 
impact upon an individual’s ability to adjust to life with a physical health condition, such 
as MS7. One of these psychological processes, grounded in social-cognitive theory, is 
self-efficacy. Differentiated from outcome expectancies, i.e., the understanding that 
performing a behaviour will lead to a specific outcome8, self-efficacy expectations refers 
to the degree to which an individual believes that they are able to perform a task in order 
to produce a desired outcome9.  Self-efficacy is one of the major determinants of peoples 
choice of activities, how much effort they expend in a task, and how long they persist in 
the face of difficulties9,10. Yet, possibly due to the unpredictable nature of the disease, 
people with MS experience lower levels of self-efficacy than people with other physical 
health conditions, including spinal cord injury11. 
 
Research suggests that self-efficacy is associated with health-related quality of life, 
depression, and social functioning12, as well as physical activity in people with MS13. 
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However, only three studies to date have investigated the relationship between self-
efficacy and cognition in people with MS. Initial research examined self-efficacy in the 
context of perceived cognitive impairment i.e., impairment as measured by patient self-
report. Research by Schmitt and colleagues in 2014 found self-efficacy to be predictive of 
perceived cognitive impairment in a sample of individuals with a range diagnostic 
subtypes12. Expanding these initial findings, longitudinal research found self-efficacy to 
remain predictive of perceived cognitive impairment over a three-year period14. Although 
depression and fatigue are associated with perceived cognitive impairment in MS15, self-
efficacy continues to be predictive of perceived cognitive impairment even when these 
variables are controlled for14. 
 
More recent research has begun to consider the relationship between self-efficacy and 
objective cognitive functioning, i.e., cognitive ability as measured using computer or 
clinician administered neuropsychological assessments. Using a sample of participants 
with clinically isolated syndrome or early relapsing-remitting MS, Jongen and colleagues 
(2015) found self-efficacy to be associated with power of attention, reaction time 
variability, and speed of memory, using a computerised battery of cognitive tests16. The 
findings suggest that self-efficacy positively affects performance on cognitive tests, 
particularly in the cognitive domains most typically affected by MS16.  The authors also 
hypothesised that cognitive ability may impact upon self-efficacy, in that individuals with 
greater cognitive capacity may feel better able to manage their symptoms as compared to 
individuals with impaired cognition16.  
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Cognitive impairments are reported to occur in approximately 45-65% of people with 
MS, and commonly include deficits in attention, memory, and executive functioning17. 
The impact of cognitive impairment is wide spread, and includes a greater risk of 
unemployment, reduced engagement in social activities, and increased difficulties 
undertaking activities of everyday living18. Therefore, understanding psychological 
variables associated with cognition is essential in order to continue to develop self-
management interventions that are grounded in the evidence base.  
 
The primary aim of this study was to address the current gaps in the research literature by 
investigating whether self-efficacy remains predictive of perceived cognitive impairment, 
even when objective cognitive functioning has been controlled for. Secondly, this study 
aimed to add to the currently limited literature base by examining the relationship 
between self-efficacy and objective cognitive functioning using ecologically valid 
measurement tools. 
 
Methods 
 
Participants  
The participant sample (n = 25) was recruited from National Health Service clinics and 
from local branches of the MS Society, based within a semi-rural area in North Wales, 
United Kingdom. Eligible participants were those with a diagnosis of MS, aged ≥ 18 
years, of fluent English language, and with sufficient cognitive and motor ability to 
complete neuropsychological assessment. Exclusion criteria included co-morbid 
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neurological diagnoses (including diagnosis of a dementia syndrome), current substance 
misuse, and significant current mental health difficulties that would impact upon capacity 
to provide informed consent.  
 
Measures 
Clinical Measures. Participants completed five questionnaire measures. 
Self-efficacy. Self-efficacy was measured using the Liverpool Self-efficacy Scale1. This is 
an 11-item Likert-type scale, consisting of two domains of control and personal agency. 
The scale has been validated using a sample of people with MS; the authors report good 
internal consistency (α = 0.81) and acceptable test-retest reliability (intraclass correlation 
coefficient of 0.79)1. Low scores on this scale are associated with low self-efficacy.   
Perceived cognitive impairment. The Cognitive Function questionnaire of the Quality of 
Life in Neurological Disorders2 (Neuro-QOL) short-form measure (version 2) assesses 
both executive function and general concerns (e.g., attention, memory, planning, and 
organising), and consists of 8 items scored on a 5-point Likert scale. This short-form 
measure allows for raw scores to be converted into standardised T scores (M = 50, SD = 
10). Higher scores denote less perceived cognitive difficulty.  
Multiple Sclerosis subtype and neurological impairment. MS subtype was assessed using 
self-report. Where participants were unsure as to their diagnosis, their MS specialist nurse 
was consulted (with written consent) to obtain this information. Neurological impairment 
was assessed using the Multiple Sclerosis Questionnaire19. This 17-item questionnaire 
has been demonstrated to be highly cross-correlated with other measures of impairment 
in MS and is therefore recommended as a valid and accurate measure19.  
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Fatigue. The Patient-Reported Outcomes Measurement Information System (PROMIS) 
Fatigue short form for MS was administered to assess fatigue20. This measure includes 8 
items scored using a 5-point Likert scale. Raw scores are converted to standardised T 
scores (M = 50, SD = 10). The PROMIS measures have been shown to be valid for use 
with people with MS21. Higher scores on this measure are associated with greater levels 
of fatigue.  
Depression. Symptoms associated with depression were assessed using the Patient Health 
Questionnaire (PHQ-9)22. This 9-item measure is scored using a 4-point Likert-type 
scale. The PHQ-9 has been validated for use in a MS sample23. Higher scores are 
associated with greater symptoms of depression.  
 
Neuropsychological measures. Participants completed a series of neuropsychological 
assessments, covering a breadth of cognitive domains. 
Attention. The Paced Auditory Serial Additions Test (PASAT)24 was initially developed 
as a measure of information processing speed and flexibility. It has since been adapted25, 
and subsequently has been extensively used within the MS population as a measure of 
attention. Participants are presented with a series of single-digit numbers using a pre-
recorded tape, and are required to add the most recent number to the one presented 
immediately before it. Participants are not required to keep a running total, but to provide 
the sum of the last two numbers heard. There are two subtests, and the numbers are 
presented at a rate of every three seconds on the first subtest and every two seconds on 
the following subtest. On each subtest, participants are presented with a total of 60 
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numbers.  The PASAT has demonstrated good internal consistency26. High scores 
represent greater attentional abilities.  
Processing Speed. The symbol search and coding subtests of the Wechsler Adult 
Intelligence Scale fourth edition (WAIS-IV)26 were administered as a measure of speed 
of information processing. The symbol search subtest assesses both processing speed and 
visual perception. On the symbol search subtest, participants are required to scan a series 
of symbols presented sequentially in a row, and identify whether they match a target 
symbol. On the coding subtest, participants are required to translate symbols, each 
uniquely associated with a number, into boxes. Both the symbol search and coding 
subtests are timed tasks of two minutes each, and therefore participants are encouraged to 
work as quickly and accurately as possible. Scores on the symbol search and coding 
subtests are converted into a processing speed index score (M = 100, SD = 15). Higher 
scores reflect a quicker processing speed.  
Memory. The Logical Memory subtests of the Wechsler Memory Scale fourth edition 
(WMS-IV)28 were administered as a measure of immediate and delayed verbal memory. 
The researcher read two short stories, which participants were required to recall both 
immediately and after a 30-minute delay. There are two versions available, one for adults 
(16-69 years) and one for older adults (aged 65-90 years). These were administered 
accordingly given the participant’s age. Higher scores indicate greater recall.  
Executive Function. Executive functioning was measured using the 6 Elements Test of 
the Behavioural Assessment of the Dysexecutive Syndrome (BADS)29. This is a set task 
of ten minutes in which participants are instructed to undertake three different types of 
tasks, a dictation task, a picture-naming task, and an arithmetic task. Participants are 
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advised to adhere to specific rules throughout the task, with points deducted if the rules 
are not observed. Low scores represent executive dysfunction.  
 
Procedure 
Ethical approval was obtained from the School of Psychology, Bangor University, and 
from the Research and Ethics Committee of local Health Board. Participants were 
recruited via three methods: Potential participants who met the eligibility criteria were 
approached during their routine National Health Service (NHS) MS nurse appointment, 
and the third author approached potential participants at their NHS clinical psychology 
appointment. The first author also contacted the local branches of the MS Society and 
presented details about the research study at Society meetings. Potential participants were 
provided with a bilingual (English and Welsh) information pack, containing an 
information sheet and an initial contact form. Interested participants were advised to 
return the initial contact form to the first author using a freepost envelope provided in the 
information pack. Upon receipt of the initial contact form, participants were contacted via 
telephone and a research appointment was arranged. Appointments took place within 
NHS premises or within the participants’ own home. Written consent was obtained at the 
start of the appointment, and subsequently, the questionnaire and neuropsychological 
measures were administered. Measures were completed over 1-3 appointments as 
requested by the research participant to accommodate for participant fatigue. Recruitment 
and testing took place between September 2016 and March 2017.  
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Data analyses  
The Statistical Package for the Social Sciences (SPSS) version 23 was used to perform all 
analyses. In order to create a single measure of objective cognitive functioning, tests 
measuring the four individual cognitive domains (i.e., attention, processing speed, 
memory, executive function) were standardised and averaged, before the four cognitive 
domain scores were averaged to create a single measure. Specifically, the raw scores for 
each neuropsychological assessment were converted into standardised scores using 
normative data. The WMS-IV Logical Memory subtest raw scores were converted into 
scaled scores using normative data based upon age (M = 10, SD = 3). These two scaled 
scores were each transformed into z scores. An average of the two z scores was then 
calculated to produce an overall z score for verbal memory. For the WAIS-IV symbol 
search and coding subtests, again, each raw score was converted into a scaled score using 
normative data based upon age (M = 10, SD = 3). The sum of the two scaled scores were 
then transformed into a processing speed composite score (M = 100, SD = 15). A final z 
score for processing speed was then calculated from the composite score.  Scores on the 
PASAT and the BADS 6 Elements Test were converted into z scores to generate a total 
score for attention and executive functioning respectively. Finally, the z scores for each 
cognitive domain were averaged, using the mean, to create a unified measure of objective 
cognitive functioning (M = 0, SD = 1). 
 
The primary aim of this study was to determine whether self-efficacy remains predictive 
of perceived cognitive impairment, even when objective cognitive functioning has been 
controlled for. This aim was addressed using hierarchical regression analyses, with 
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perceived cognitive impairment as the outcome variable, and objective cognitive 
functioning and self-efficacy as the predictor variables. Objective cognitive functioning 
was entered into the regression model at stage 1 (Model 1), and self-efficacy was entered 
into the model at stage 2 (Model 2). This study also aimed to further examine the 
relationship between self-efficacy and objective cognitive functioning. Therefore 
correlational analyses were performed between self-efficacy and the cognitive domains of 
attention, processing speed, memory, and executive functioning. The data were initially 
examined to determine whether the assumptions for parametric analyses were met, and 
either Pearson’s product or Spearman’s rho analyses were performed, dependent upon 
whether the data were normally distributed.  
 
Results 
 
Participants 
Descriptive statistics for demographic variables, self-efficacy, fatigue, perceived 
cognitive impairment, and depression are presented in Table 1. The majority of 
participants were female (n = 18), and all participants were aged between 31 and 78 (M = 
52.92, SD = 12.96). Ten participants had a diagnosis of relapsing-remitting MS (40%), 
nine participants had a diagnosis of secondary progressive MS (36%), and six 
participants had a diagnosis of primary progressive MS (24%). Participants had 
experienced symptoms of MS for between 33 and 480 months (M = 185.68, SD = 
111.28), and had received a diagnosis of MS between 22 and 300 months prior to 
undertaking the research project (M = 132.16, SD = 91.30).  
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Table 1. 
Descriptive statistics for demographic and disease-related variables, fatigue, depression, 
self-efficacy, and perceived cognitive impairment 
 
Details regarding neurological impairment for the sample are provided in Table 2. Based 
upon the mean score on the PHQ-9, the sample was experiencing a mild to moderate 
level of depression. Perceived cognitive impairment and fatigue fell within one standard 
deviation of the population mean. Group means and standard deviations for performance 
on neuropsychological assessments are displayed in the appendix.   
 
 
 
 Values (n = 25) 
Education level  
School or less 8 (32) 
College course or equivalent 7 (28) 
University degree or higher 10 (40) 
Employment Status  
Employed full time 7 (28) 
Unemployed 3 (12) 
Retired/retired on ill-health grounds 15 (60) 
Ethnicity  
White British 21 (84) 
Welsh 1 (4) 
Other ethnicity  3 (12) 
PROMIS-Fatigue 58.85 ± 10.52 (34.7, 81.3) 
PHQ-9 9.6 ± 7.14 (0, 26) 
Liverpool Self-efficacy Scale   
Control subscale 15.76 ± 4.42 (7, 24) 
Personal agency subscale 13 ± 3.01 (6, 20) 
Total score 28.76 ± 6.95 (14, 44) 
NeuroQOL-Cognitive Function 42.72 ± 7.72 (25.9, 56.3) 
Note. Values are mean ± SD (minimum, maximum) or n (%). 
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Table 2. 
Neurological impairment (MS Questionnaire19)  
 
Regression analysis 
A hierarchical regression analysis revealed that objective cognitive functioning only 
explained 12% of the variance in perceived cognitive impairment, and this model (Model 
1) was not significantly better than chance (F(1,23) = 3.15, p = .089). When both objective 
cognitive functioning and self-efficacy were entered at stage 2 (Model 2), they explained 
45% of the variance and significantly contributed to the model (F(1,22) = 8.92, p =.001). 
The regression analysis is detailed in Table 3.   
 
 
                                                                                      (%) 
Require an aid to walk 48 
Uses a wheelchair for almost all activities 16 
Mild weakness 12 
Moderate or severe weakness 64 
Mildly impaired sensation 28 
Moderately or severely impaired sensation 56 
Mildly impaired visual acuity 4 
Moderately or severely impaired visual acuity 12 
Mildly uncoordinated 32 
Moderately or severely uncoordinated 24 
Mild difficulties with speech 12 
Moderate or severe difficulties with speech 12 
Mild difficulty with balance 16 
Moderate or severe difficulty with balance 68 
Mild spasticity and/or spasms 40 
Moderate or severe spasticity and/or spasms 48 
Mild difficulty with swallowing 32 
Moderate or severe difficulty with swallowing 4 
Difficulties with bowel or bladder function 76 
Mild dizziness or vertigo 32 
Moderate to severe dizziness or vertigo 12 
 60 
Table 3. 
Regression analyses 
 Model 1 Model 2 
Variable B SE B β B SE B β 
Constant  44.46 1.78 - 19.90 6.95 - 
OCF 2.67 1.50 .35 -0.48 1.49 -.06 
Self-efficacy - - - 0.78 0.22 .70** 
Adjusted R2 - .08 - - .40 - 
R2 Change - .12 - - .33 - 
F Change - 3.15 - - 13.05 - 
Note. OCF, objective cognitive functioning; **p = .002 
 
Correlational analyses 
Correlational analysis between self-efficacy and cognitive domains 
A significant relationship between self-efficacy and processing speed was found on both 
the personal agency subscale and the total self-efficacy score. A significant relationship 
between executive function and both the control subscale and self-efficacy total score 
was also found. No other significant relationships were found between self-efficacy and 
cognitive domains. All correlational analyses are demonstrated in Table 4. 
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Table 4. 
Correlational analyses between self-efficacy and cognitive domains 
                          Cognitive Domain 
 Attention Processing Speeda Memory Executive Function 
Control .11 .33 .31 .49* 
Personal agency .31 .51** .34 .26 
Total self-efficacy 
 
.15 .43* .33 
 
.42* 
Note. **p<. 01, *p<. 05 (2-tailed) 
All values are Spearman’s rho, unless otherwise stated 
a =Pearson’s r 
 
Discussion 
 
Extending previous research 12,14,, this study found self-efficacy significantly predicts 
perceived cognitive impairment in individuals MS, even when controlling for objective 
cognitive functioning. In this sample, objective cognitive functioning was not a 
significant predictor of perceived cognitive impairment. This may be due to discrepancy 
between perceived and objective cognitive impairment found in individuals with MS30.  
The relationship between self-efficacy and specific cognitive domains was also 
investigated. Unlike previous research by Jongen and colleague (2015)16, there was not a 
significant relationship between attention and self-efficacy, although this may be due to 
differences in measurement. However, this study found a significant relationship between 
processing speed and self-efficacy, and executive functioning and self-efficacy. One of 
the strengths of this study was the use of ecologically valid measures of objective 
cognitive functioning. Furthermore, this study adds to the current literature on self-
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efficacy and objective cognitive functioning by including people with a wider variety of 
diagnostic subtypes. 
 
The findings from this study have both clinical and research implications. With regard to 
research implications, this study was the first to examine whether self-efficacy remains 
predictive of perceived cognitive impairment, whilst controlling for objective cognitive 
functioning. This study may therefore benefit from replication to ensure the findings are 
robust. With regard to clinical practice, clinicians may wish to consider whether self-
management interventions, aimed at enhancing self-efficacy, reduce perceived cognitive 
impairment. Such studies would need to be carefully evaluated to determine their 
effectiveness. However, this is a meaningful area of rehabilitative work that has the 
potential to improve health outcomes for people with MS.  
 
Study limitations 
Previous research has found perceived cognitive impairment to be associated with 
depression and fatigue in individuals with MS15. However, due to the relatively small 
sample size and therefore limited statistical power of this study, depression and fatigue 
were not entered into the regression analysis. In addition, no demographic or disease-
related variables were entered in to the regression model. However, previous research has 
not found a relationship between demographic variables (including age and diagnostic 
subtype) and self-efficacy in a sample of people with MS1. It is therefore possible that 
these variables would not have significantly contributed to the regression model. 
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Due to the cross-sectional design of this study, it is not possible to infer the direction of 
causality between self-efficacy and perceived cognitive impairment. Indeed, some 
authors have proposed that cognitive ability may affect self-efficacy, as opposed to self-
efficacy affecting cognition16. Longitudinal research would be required to address this 
question. This study also assessed self-efficacy for MS in terms of sense of control and 
personal agency, as opposed to self-efficacy specifically in regard to cognition. However, 
participants were aware that they had consented to take part in a study on self-efficacy 
and cognition, and so it is reasonable to infer that they completed the self-efficacy 
measure with cognition in mind. Finally, due to the relatively small sample size included 
in this study, one should interpret the findings with some cautiousness.  
 
Conclusion 
 
The present study was the first to examine the role of objective cognitive functioning in 
the relationship between self-efficacy and perceived cognitive impairment in people with 
MS. This study found that self-efficacy was predictive of perceived cognitive 
impairment, and remained so after controlling for objective cognitive functioning. There 
was a significant relationship between processing speed and self-efficacy, and executive 
functioning and self-efficacy; this study did not find a significant relationship between 
attention and self-efficacy, or verbal memory and self-efficacy. 
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Figure 1. Funnel plot for fatigue 
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Figure 2. Funnel plot for self-efficacy 
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Table 1. 
Means and standard deviations for neuropsychological assessment scores (non 
transformed) 
 
Measure M ± SD Range 
PASAT A 3” Total Correct Raw Score 35.83 ± 12.57 16 - 60 
PASAT A 2” Total Correct Raw Score 28.38 ± 9.65  10 - 50 
WAIS-IV Symbol Search   25.44 ± 7.32 9 - 38 
WAIS-IV Coding 56.75 ± 18.11 32 - 101 
WMS-IV Logical Memory 1 (Adults)  24.55 ± 6.91  13 - 36 
WMS-IV Logical Memory 1 (Older adults) 34.25 ± 10.15 22 - 44 
WMS-IV Logical Memory 2 (Adults) 19.65 ± 8.06 5 - 34 
WMS-IV Logical Memory 2 (Older adults) 18.50 ± 8.10 11 - 26 
BADS 6 Elements Profile Score 3.08 ± 1.32 0 - 4 
Note. BADS, Behavioural Assessment of the Dysexecutive Syndrome; PASAT, Paced Auditory 
Serial Additions Test; WAIS, Wechsler Adult Intelligence Scale; WMS, Wechsler Memory Scale.  
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Gwasanaeth Moeseg Ymchwil 
Research Ethics Service 
 
 
Pwyllgor Moeseg Ymchwil Cymru 5 
Wales Research Ethics Committee 5 
Bangor 
 
Clinical Academic Office  
Ysbyty Gwynedd Hospital 
Betsi Cadwaladr University Health Board 
Bangor, Gwynedd 
LL57 2PW 
Telephone/ Facsimile: 01248 - 384.877  
Email: Rossela.Roberts@wales.nhs.uk    
: 
24 June 2016 
 
 
Mrs Laura E Spencer 
Trainee Clinical Psychologist 
Betsi Cadwaladr University Heath Board 
Clinical Psychology Programme 
School of Psychology 
Bangor University, Bangor, Gwynedd 
LL57 2AS  psp4eb@bangor.ac.uk 
 
 
Dear Mrs Spencer,  
 
Study title: Self-efficacy and cognition in people with a diagnosis of 
 Multiple Sclerosis. 
REC reference: 16/WA/0186 
IRAS project ID: 196799 
 
 
Thank you for your letter of 20 June 2016, responding to the Committee’s request for further 
information on the above research and submitting revised documentation. 
 
The further information has been considered on behalf of the Committee by the Chair. 
 
We plan to publish your research summary wording for the above study on the HRA website, 
together with your contact details. Publication will be no earlier than three months from the date 
of this opinion letter.  Should you wish to provide a substitute contact point, require further 
information, or wish to make a request to postpone publication, please contact the REC 
Manager, Dr Rossela Roberts, rossela.roberts@wales.nhs.uk  
 
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above 
research on the basis described in the application form, protocol and supporting documentation 
as revised, subject to the conditions specified below. 
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Conditions of the favourable opinion 
 
The REC favourable opinion is subject to the following conditions being met prior to the start 
of the study. 
 
Management permission must be obtained from each host organisation prior to the start of 
the study at the site concerned. 
 
Management permission should be sought from all NHS organisations involved in the study 
in accordance with NHS research governance arrangements. Each NHS organisation must 
confirm through the signing of agreements and/or other documents that it has given 
permission for the research to proceed (except where explicitly specified otherwise).  
Guidance on applying for NHS permission for research is available in the Integrated 
Research Application System, www.hra.nhs.uk or at http://www.rdforum.nhs.uk.   
 
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites ("participant identification centre"), guidance should be sought 
from the R&D office on the information it requires to give permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation.  
 
Sponsors are not required to notify the Committee of management permissions from host 
organisations 
 
Registration of Clinical Trials 
 
All clinical trials (defined as the first four categories on the IRAS filter page) must be 
registered on a publically accessible database within 6 weeks of recruitment of the first 
participant (for medical device studies, within the timeline determined by the current 
registration and publication trees).   
 
There is no requirement to separately notify the REC but you should do so at the earliest 
opportunity e.g. when submitting an amendment.  We will audit the registration details as part 
of the annual progress reporting process. 
 
To ensure transparency in research, we strongly recommend that all research is registered 
but for non-clinical trials this is not currently mandatory. 
 
If a sponsor wishes to contest the need for registration they should contact Catherine Blewett 
(catherineblewett@nhs.net), the HRA does not, however, expect exceptions to be made. 
Guidance on where to register is provided within IRAS.  
 
It is the responsibility of the sponsor to ensure that all the conditions are complied 
with before the start of the study or its initiation at a particular site (as applicable). 
 
 
 
Ethical review of research sites 
 
NHS sites 
 
The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the start of 
the study (see "Conditions of the favourable opinion" above). 
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User Feedback 
 
The Health Research Authority is continually striving to provide a high quality service to all applicants 
and sponsors. You are invited to give your view of the service you have received and the application 
procedure. If you wish to make your views known please use the feedback form available on the HRA 
website: http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/    
 
 
 
HRA Training 
 
We are pleased to welcome researchers and R&D staff at our training days – see details at 
http://www.hra.nhs.uk/hra-training/   
 
 
 
16/WA/0186                          Please quote this number on all correspondence 
 
 
With the Committee’s best wishes for the success of this project. 
 
Yours sincerely 
 
 
Dr Philip Wayman White, MBChB, MRSM 
Chair 
E-mail: rossela.roberts@wales.nhs.uk 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enclosures: “After ethical review – guidance for  researchers” 
 
 
 
 Copy:  Sponsor: Hefin Francis  
   School of Psychology 
   Adeilad Brigantia, Penrallt Road  
   Bangor University, Bangor  
   LL57 2GD h.francis@bangor.ac.uk 
 
 R&D Office:  Miss Debra Slater 
`   R&D Office 
   Betsi Cadwaladr University Health Board 
   Ysbyty Gwynedd,  
   Bangor, LL57 2PW  debra.slater@wales.nhs.uk 
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Attached you will find a set of approval conditions outlining your responsibilities during the course of
this research. Failure to comply with the approval conditions will result in the withdrawal of the
approval to conduct this research in the Betsi Cadwaladr University Health Board.
If your study is adopted onto the NISCHR Clinical Research Portfolio (CRP), it will be a condition of
this NHS research permission, that the Chief Investigator will be required to regularly upload
recruitment data onto the portfolio database. To apply for adoption onto the NISCHR CRP, please
go to: http://www.wales.nhs.uk/sites3/page.cfm?orgid=580&pid=31979. Once adopted, NISCHR
CRP studies may be eligible for additional support through the NISCHR Clinical Research Centre.
Further information can be found at:
http://www.wales.nhs.uk/sites3/page.cfm?orgid=580&pid=28571 and/or from your NHS R&D office
colleagues.
To upload recruitment data, please follow this link:
http://www.crncc.nihr.ac.uk/about_us/processes/portfolio/p_recruitment. Uploading recruitment data
will enable NISCHR to monitor research activity within NHS organizations, leading to NHS R&D
allocations which are activity driven. Uploading of recruitment data will be monitored by your
colleagues in the R&D office.
If you need any support in uploading this data, please contact debra.slater@wales.nhs.uk or
sion.lewis@wales.nhs.uk
If you would like further information on any other points covered by this letter please do not hesitate
to contact me.
On behalf of the Panel, I would like to take this opportunity to wish you every success with your
research.
Yours sincerely,
Dr. Rossela Roberts, MICR, CSci
Clinical Governance Officer (R&D/Ethics)
Copy to:
Academic Supervisor: Dr Craig Roberts
The North Wales Brain Injury Service
Hesketh road
Colwyn Bay
Conwy
LL29 8AY craig.roberts@wales.nhs.uk
Sponsor: Hefin Francis
School of Psychology#Brigantia Buildings
Bangor University
Bangor
LL57 2AS h.francis@bangor.ac.uk
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Participant Information Sheet	
 
Study title: Self-efficacy and cognition in people with Multiple Sclerosis 
Name of researcher:  Laura Spencer, Trainee Clinical Psychologist 
Supervised by: Dr Craig Roberts, Clinical Neuropsychologist 
 
We would like to invite you to take part in our research. Before you decide, please 
take time to read the following information about what this would involve for you. 
Thank you. 
 
What is the purpose of this study? 
We are interested in how people’s thinking skills (e.g., memory and problem solving) 
may be affected by self-efficacy, or how well one believes that they are able to 
perform a task. We are also interested in understanding how people’s thinking skills 
may be affected by fatigue and mood, and by the severity of their symptoms of 
multiple sclerosis. We hope this research will help us to support people with multiple 
sclerosis more effectively in the future. 
 
Why have I been invited to participate? 
You have been invited to participate because you have a diagnosis of multiple 
sclerosis, and you have attended an appointment at one of the multiple sclerosis 
clinics.   
 
What would taking part involve? 
If you decide that you may be interested in taking part our research, please complete 
the initial contact form enclosed, and return using the stamped addressed envelope 
provided. If you return the initial contact form, Laura will contact you by telephone 
approximately one week later to discuss the study further and answer any questions 
you may have. At the end of the conversation, Laura will ask if you would like to 
participate in the study.  
If you are still interested in taking part, Laura will arrange to meet with you in person 
at a convenient time and date. This may be at your own home, at the North Wales 
Brain Injury Service in Colwyn Bay, or at another NHS building (whichever is 
preferable to you).  
In the appointment you will be asked to complete a series of short questionnaires 
about self-efficacy, your mood, levels of fatigue, symptoms of multiple sclerosis, and 
your thinking skills. You will also be asked to complete some tasks to look at your 
thinking skills, e.g., we may ask you to remember a short story. The appointment will 
last no longer than two hours, but could be split over two shorter appointments if you 
would prefer. 
 
What are the possible benefits of taking part? 
There is no direct benefit to yourself from taking part however your participation will 
have the potential of benefitting people with multiple sclerosis in the future.  
RHAGLEN SEICOLEG CLINIGOL GOGLEDD CYMRU 
NORTH WALES CLINICAL PSYCHOLOGY PROGRAMME 
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What are the possible disadvantages and risks of taking part? 
It is anticipated that the study will take no longer two hours of your time. Sometimes 
people can find it difficult to complete some of the tasks, which could be frustrating 
or upsetting. You will also be asked to complete a questionnaire about your mood and 
symptoms of multiple sclerosis, which might raise some difficult emotions. If you 
find this is the case for you then we would encourage you to speak to your clinician at 
the multiple sclerosis clinic or your GP. If you find you are becoming upset then we 
can stop at any time. You can also choose to withdraw from the study should you 
wish. 
 
Will taking part in the study affect the care I receive in the NHS? 
Taking part in the study will not affect the care that you receive in the NHS. If you 
agree to take part in this research, I will notify your G.P. and Mrs. Yvonne Copeland, 
MS specialist nurse. This is to ensure your safety and well-being. With your 
permission, I may collect information about your symptoms of multiple sclerosis from 
your medical records.  
 
Who is organising and funding this study? 
This study is organised and funded by the North Wales Clinical Psychology 
Programme at Bangor University. 
 
Who has reviewed this study? 
The study has been reviewed and approved by an independent panel of people from 
the School of Psychology at Bangor University, and from the NHS Research Ethics 
Committee. 
 
What if something goes wrong? 
If you have any concerns about the research study, you may contact Laura Spencer 
via telephone on 07972763722 or via e-mail at psp4eb@bangor.ac.uk. You may also 
wish to contact Dr. Craig Roberts, Clinical Neuropsychologist, at the North Wales 
Brain Injury Service via telephone on 01492 807770 or via e-mail at 
Craig.Roberts@Wales.nhs.uk  
 
If neither Laura nor Dr. Roberts are able to address your concerns satisfactorily and/or 
you wish to raise a complaint about the study, please contact Mr. Hefin Francis, 
School of Psychology Manager: 
 
Mr. Hefin Francis 
School of Psychology Manager 
Bangor University, 
School of Psychology, 
Brigantia Building, 
 
 
Tel: 01248 388339 
E-mail: h.francis@bangor.ac.uk  
Penrallt Road, 
Gwynedd, 
LL57 2DG. 
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What will happen if I don’t want to carry on with the study? 
You may withdraw from the study at any time, without giving any reason, and 
without your care in the NHS being affected in any way. Should you wish to 
withdraw, you can also ask for your data to be removed from the study.  
 
How will my information be kept confidential? 
All information collected will be kept confidentially. The only exceptions to 
confidentiality are where there are concerns about your safety, or that of somebody 
else’s, then Laura will have a duty to share this information with other professionals. 
Where incidental disclosures are made, it may also be necessary to share this 
information with other professionals. In these circumstances, Laura will make every 
effort to inform you about this first. The data collected will be stored securely and 
separately from your personal details. Only Laura and Dr. Craig Roberts will have 
access to the data, and data will be destroyed upon completion of the project in 
accordance with NHS guidelines.  
 
What will happen to the results of this study? 
The results of the study will be used to write a report for Bangor University as part of 
the Doctoral training programme. Laura Spencer may also write a report for 
publication in a scientific journal. If you wish, you will be able to receive a letter 
detailing the results of the study in the post. All information about participants will be 
anonymous, so you will not be identifiable in any written documentation.  
 
 
Thank you for taking the time to read this information sheet. 
 
 
Yours Sincerely, 
 
 
Laura Spencer        Supervised by Dr. Craig Roberts 
Trainee Clinical Psychologist      Clinical Neuropsychologist 
 
 129 
 
 
 
 
 
 
 
COLEG IECHYD A GWYDDORAU YMDDYGIAD	
COLLEGE OF HEALTH & BEHAVIOURAL SCIENCES	
	
YSGOL SEICOLEG	
SCHOOL OF PSYCHOLOGY  	
Participant Information Sheet v.3	
Page 1 of 3	
20.06.2016	
Bangor University Ethics Application Number: 15686	
	
Taflen wybodaeth i gyfranogwyr 
	
Teitl yr astudiaeth: Hunaneffeithlonrwydd a gwybyddiaeth mewn pobl â Sglerosis 
Ymledol	
Enw’r ymchwilydd:  Laura Spencer, Seicolegydd Clinigol dan Hyfforddiant	
Dan oruchwyliaeth: Dr Craig Roberts, Niwroseicolegydd Clinigol	
	
Hoffem eich gwahodd i gymryd rhan yn ein hymchwil. Cyn i chi benderfynu, 
cymerwch amser i ddarllen y wybodaeth isod ynglŷn â'r hyn y byddai'n ei olygu i chi. 
Diolch.	
	
Beth yw diben yr astudiaeth hon?	
Mae gennym ddiddordeb yn y ffordd y gall sgiliau meddwl pobl (e.e. cof a datrys 
problemau) gael eu heffeithio gan hunaneffeithlonrwydd, neu ba mor dda y mae 
rhywun yn credu y gallant wneud tasg. Mae gennyf ddiddordeb hefyd mewn deall sut 
y gall sgiliau meddwl pobl gael eu heffeithio gan flinder a thymer, a chan ba mor 
ddifrifol yw eu symptomau o sglerosis ymledol. Rydym yn gobeithio y bydd yr 
ymchwil hwn yn ein helpu i gefnogi pobl sydd â sglerosis ymledol yn fwy effeithiol 
yn y dyfodol.	
	
Pam y gofynnwyd imi gymryd rhan?	
Rydych wedi cael gwahoddiad i gymryd rhan oherwydd eich bod wedi cael diagnosis 
o sglerosis ymledol.  	
	
Beth y byddai cymryd rhan yn ei olygu?	
Os penderfynwch y byddai gennych ddiddordeb cymryd rhan yn yr ymchwil, llenwch 
y ffurflen cyswllt cyntaf amgaeedig, a’i dychwelyd yn yr amlen barod a ddarperir. Os 
byddwch yn dychwelyd y ffurflen cyswllt cyntaf, bydd Laura yn cysylltu â chi drwy 
eich ffonio tua wythnos yn ddiweddarach i drafod yr astudiaeth ymhellach ac ateb 
unrhyw gwestiynau sydd gennych. Ar ddiwedd y sgwrs, bydd Laura yn gofyn a 
hoffech gymryd rhan yn yr astudiaeth. 	
Os bydd dal gennych chi ddiddordeb mewn cymryd rhan, bydd Laura yn trefnu i'ch 
cyfarfod yn bersonol ar adeg ac mewn lle cyfleus. Gall hyn fod yn eich cartref eich 
hun, yng Ngwasanaeth Anaf i’r Ymennydd Gogledd Cymru ym Mae Colwyn, neu 
adeilad GIG arall (pa un bynnag sydd orau gennych chi). 	
Yn yr apwyntiad gofynnir ichi lenwi cyfres o holiaduron byr ynglŷn â'ch 
hunaneffeithlonrwydd, eich tymer, lefelau blinder, symptomau o sglerosis ymledol 
a'ch sgiliau meddwl. Gofynnir i chi hefyd wneud ychydig o dasgau er mwyn gweld 
eich sgiliau meddwl, e.e. gallwn ofyn i chi gofio stori fer. Ni fydd yr apwyntiad yn 
para mwy na dwy awr, ond gellir ei rannu i ddau apwyntiad byrrach os byddai'n well 
gennych. 
	
 
RHAGLEN SEICOLEG CLINIGOL GOGLEDD CYMRU 
NORTH WALES CLINICAL PSYCHOLOGY PROGRAMME 
	
 130 
 
 
 
 
 
 
 
 
COLEG IECHYD A GWYDDORAU YMDDYGIAD	
COLLEGE OF HEALTH & BEHAVIOURAL SCIENCES	
	
YSGOL SEICOLEG	
SCHOOL OF PSYCHOLOGY  	
Participant Information Sheet v.3	
Page 2 of 3	
20.06.2016	
Bangor University Ethics Application Number: 15686	
Beth yw’r manteision posibl o gymryd rhan?	
Nid oes unrhyw fudd uniongyrchol i chi o gymryd rhan ond mae'n bosibl y bydd eich 
cyfranogiad o fudd i bobl gyda sglerosis ymledol yn y dyfodol. 	
	
Beth yw’r anfanteision a’r risgiau posib o gymryd rhan?	
Rhagwelir na fydd yr astudiaeth yn cymryd mwy na dwy awr o'ch amser. Weithiau 
gall fod yn anodd i bobl gyflawni rhai o'r tasgau, a gall hyn fod yn rhwystredig neu'n 
achosi gofid. Gofynnir i chi hefyd lenwi holiadur am eich tymer a symptomau 
sglerosis ymledol, a all ysgogi rhai emosiynau anodd.  Os bydd hyn yn wir i chi, yna 
byddem yn eich annog i siarad â'ch clinigwr yn y clinig sglerosis ymledol neu â'ch 
meddyg teulu. Os bydd yn achosi gofid i chi, gallwn roi'r gorau iddi ar unrhyw adeg. 
Gallwch hefyd dynnu'n ôl o'r astudiaeth os dymunwch.	
	
Fydd cymryd rhan yn yr astudiaeth yn effeithio ar y gofal a dderbyniaf yn y 
GIG?	
Ni fydd cymryd rhan yn yr astudiaeth yn effeithio ar y gofal a dderbyniwch yn y GIG. 
Os ydych yn cytuno i gymryd rhan yn yr ymchwil hwn, byddaf yn rhoi gwybod i'ch 
meddyg teulu a Mrs. Yvonne Copeland, nyrs arbenigol MS. Mae hyn er mwyn 
sicrhau eich diogelwch a'ch lles. Gyda'ch caniatâd, gallaf gasglu gwybodaeth am eich 
symptomau o sglerosis ymledol o'ch cofnodion meddygol. 	
	
Pwy sy’n trefnu ac yn cyllido’r astudiaeth hon?	
Trefnir ac ariannir yr astudiaeth hon gan Raglen Seicoleg Glinigol Gogledd Cymru, 
ym Mhrifysgol Bangor.	
	
Pwy sydd wedi adolygu’r astudiaeth hon?	
Mae’r astudiaeth wedi’i hadolygu a’i chymeradwyo gan banel annibynnol o bobl yn 
yr Ysgol Seicoleg ym Mhrifysgol Bangor, ac o Bwyllgor Moeseg Ymchwil y GIG. 	
	
Beth os aiff rhywbeth o’i le?	
Os oes gennych unrhyw bryderon ynglŷn â’r astudiaeth ymchwil, gellwch gysylltu â 
Laura Spencer drwy ffonio 07972763722 neu anfon e-bost at psp4eb@bangor.ac.uk. 
Gallwch hefyd gysylltu â Dr. Craig Roberts, Niwroseicolegydd Clinigol, yng 
Ngwasanaeth Anaf i’r Ymennydd Gogledd Cymru drwy ffonio 01492 807770 neu 
anfon e-bost at Craig.Roberts@Wales.nhs.uk 	
	
Os na fydd Laura na Dr. Roberts yn gallu rhoi sylw boddhaol i'ch pryderon ac/neu 
rydych eisiau gwneud cwyn am yr astudiaeth, cysylltwch â Mr Hefin Francis, 
Rheolwr yr Ysgol Seicoleg: 	
Mr. Hefin Francis 	
Rheolwr yr Ysgol Seicoleg	
Prifysgol Bangor,	
Ysgol Seicoleg,	
Adeilad Brigantia, 
Ffordd Penrallt,	
Gwynedd,	
LL57 2DG.	
	
Ffôn: 01248 388339 	
E-bost: h.francis@bangor.ac.uk 	
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Beth fydd yn digwydd os na fyddaf yn dymuno parhau â’r astudiaeth?	
Gellwch dynnu’n ôl o’r astudiaeth ar unrhyw adeg heb roi rheswm, ac ni fydd eich 
gofal yn y GIG yn cael ei effeithio mewn unrhyw ffordd. Os byddwch yn dymuno 
tynnu’n ôl, gallwch ofyn i'ch data gael ei dynnu o'r astudiaeth hefyd. 	
	
Sut fydd fy ngwybodaeth yn cael ei chadw’n gyfrinachol?	
Bydd yr holl wybodaeth a gesglir yn cael ei chadw’n hollol gyfrinachol. Yr unig 
eithriad i gyfrinachedd yw os oes pryderon am eich diogelwch, neu ddiogelwch 
rhywun arall, yna bydd yn ddyletswydd ar Laura i rannu’r wybodaeth honno gyda 
gweithwyr proffesiynol eraill. Os datgelir rhywbeth yn ddamweiniol, efallai bydd 
rhaid rhannu’r wybodaeth hon gyda gweithwyr proffesiynol eraill hefyd. Yn yr 
amgylchiadau hyn, bydd Laura yn gwneud pob ymdrech i roi gwybod i chi yn gyntaf. 
Cedwir yr holl ddata a gesglir yn ddiogel ac ar wahân oddi wrth unrhyw fanylion 
personol amdanoch. Dim ond Laura a Dr. Craig Roberts fydd yn cael gweld y data, a 
chaiff y data eu dinistrio ar ôl cwblhau'r project yn unol â chanllawiau'r GIG. 	
	
Beth fydd yn digwydd i ganlyniadau’r astudiaeth hon?	
Defnyddir canlyniadau’r astudiaeth i ysgrifennu adroddiad i Brifysgol Bangor fel rhan 
o'r rhaglen hyfforddi ddoethurol. Efallai y bydd Laura Spencer hefyd yn ysgrifennu 
adroddiad i’w gyhoeddi mewn cylchgrawn gwyddonol. Os dymunwch, cewch lythyr 
drwy'r post yn rhoi manylion am ganlyniadau'r astudiaeth. Bydd yr holl wybodaeth 
am gyfranogwyr yn ddienw, ac ni fydd modd eich adnabod mewn unrhyw 
ddogfennaeth ysgrifenedig. 	
	
	
Diolch i chi am roi o’ch amser i ddarllen y daflen wybodaeth hon.	
	
	
Yn gywir,	
	
	
Laura Spencer     Dan oruchwyliaeth Dr. Craig Roberts	
Seicolegydd Clinigol dan Hyfforddiant   Niwroseicolegydd Clinigol	
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Participant Identification Number: 	
 
   Participant Consent Form 
 
Study title: Self-efficacy and cognition in people with Multiple Sclerosis 
 
 
Name of researcher:  Laura Spencer, Trainee Clinical Psychologist 
Supervised by: Dr Craig Roberts, Clinical Neuropsychologist 
    
 
1. I confirm that I have read the Participant Information Sheet dated 08/08/2016 
for the above study. 
 
2. I have had the opportunity to consider the information and ask questions, and I 
have had any questions answered satisfactorily. 
 
3. I understand that my participation is voluntary and that I am free to withdraw 
at any time without giving any reason, and without my care anywhere in the 
NHS being affected. 
 
4. I understand that the information collected about me may be used to support 
other research in the future at the North Wales Brain Injury Service. 
 
5. I understand that information may be shared with other professionals where 
there are concerns regarding my safety and/or the safety of other people, and 
where incidental disclosures are made. 
 
6. I give my consent for my General Practitioner to be informed that I have 
agreed to participate in this research. 
 
7. I give my consent for Mrs. Yvonne Copeland, MS Specialist Nurse, to be 
informed that I have agreed to participate in this research. 
 
8. I give my consent for Laura to access my medical records.  
 
9. I agree to take part in the above study. 
 
 
Please initial 
box 
RHAGLEN SEICOLEG CLINIGOL GOGLEDD CYMRU 
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Name of Participant      Date          Signature 
 
 
 
 
 
Name of Person      Date           Signature 
Taking Consent  
 
 134 
 
 
COLEG IECHYD A GWYDDORAU YMDDYGIAD	
COLLEGE OF HEALTH & BEHAVIOURAL SCIENCES	
YSGOL SEICOLEG	
SCHOOL OF PSYCHOLOGY  	
Participant Consent Form v.4  	
08.08.2016	
Bangor University Ethics Application Number: 15686	
Page 1 of 2  
	
RHAGLEN SEICOLEG CLINIGOL GOGLEDD CYMRU	
NORTH WALES CLINICAL PSYCHOLOGY PROGRAMME	
	
Rhif Adnabod y Cyfranogwr: 	
	
  Ffurflen Gydsynio i Rai sy’n Cymryd Rhan	
	
Teitl yr astudiaeth: Hunaneffeithlonrwydd a gwybyddiaeth mewn pobl â Sglerosis 
Ymledol	
Enw’r ymchwilydd:  Laura Spencer, Seicolegydd Clinigol dan Hyfforddiant	
Dan oruchwyliaeth: Dr Craig Roberts, Niwroseicolegydd Clinigol	
   	
	
1. Cadarnhaf fy mod wedi darllen y daflen wybodaeth i gyfranogwyr dyddiedig 
20/06/2016 ar gyfer yr astudiaeth uchod.	
	
2. Rwyf wedi cael cyfle i ystyried y wybodaeth a gofyn cwestiynau, ac wedi cael 
atebion boddhaol i unrhyw gwestiynau oedd gennyf.	
	
3. Deallaf fy mod yn cymryd rhan o’m gwirfodd, a bod gennyf hawl i dynnu’n ôl 
ar unrhyw adeg, heb roi unrhyw reswm, a heb i hynny effeithio ar fy ngofal 
mewn unrhyw ran o'r GIG.	
	
4. Deallaf y bydd y wybodaeth a gesglir amdanaf yn cael ei defnyddio i gefnogi 
ymchwil arall yn y dyfodol yng Ngwasanaeth Anaf i'r Ymennydd Gogledd 
Cymru.	
	
5. Deallaf y gellir rhannu gwybodaeth gyda gweithwyr proffesiynol eraill lle bo 
pryderon  ynghylch fy niogelwch fy hun a/neu ddiogelwch pobl eraill, a phan 
ddatgelir rhywbeth yn ddamweiniol.	
	
6. Rwy’n cytuno i’m Meddyg Teulu gael gwybod fy mod wedi cytuno i gymryd 
rhan yn yr ymchwil hon.	
	
7. Rwy’n cytuno Mrs Yvonne Copeland, Nyrs Arbenigol MS, gael gwybod fy 
mod wedi cytuno i gymryd rhan yn yr ymchwil hon.	
	
8. Rwy'n caniatau i Laura weld fy nghofnodion meddygol.	
	
9. Rwy'n cytuno i gymryd rhan yn yr astudiaeth uchod.	
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Enw’r cyfranogwr    Dyddiad    Llofnod	
	
	
	
	
	
Enw’r Unigolyn    Dyddiad    Llofnod	
yn cymryd cydsyniad 	
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Participant Identification Number:  
 
Demographic Questionnaire 
 
The following questions are designed to collect information regarding your background. Please tick the 
appropriate boxes, or write in the spaces provided. Thank you.  
 
1. Please specify your gender   
 Male   Female   Other  
 
2. What was your age in years on your last birthday? ______________________ 
3. What is your current marital status? 
Married/Civil Partnership    Cohabiting/Living with partner  
 
In a relationship but living separately   Single  
 
Divorced/Separated     Widowed  
4. How would you describe your ethnicity? (Please choose one option that best describes your ethnic group 
or background) 
White:        Black/African/Caribbean/Black British: 
Welsh/English/Scottish/Northern Irish/British  African   
Irish       Caribbean 
Gypsy or Irish Traveller   
 
Asian/Asian British:      Mixed/Multiple ethnic groups 
Indian                                                                                 White and Black Caribbean  
Pakistani                                                                             White and Black African 
Bangladeshi                                                                        White and Asian 
Chinese 
 Other ethnic group 
Arab 
Any other ethnic group, please describe __________________________ 
5. What is your first language? 
Welsh       English    
Other, please specify___________________________ 
6. What age did you start school? _______________ 
7. What age did you leave school? _______________ 
8. Do you hold any formal qualifications? (Please specify, e.g., O Level, A Level, Degree, NVQ etc) 
RHAGLEN SEICOLEG CLINIGOL GOGLEDD CYMRU 
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________________________________________________________________________________________
________________________________________________________________________________________
_______________________________________________________________ _________________________ 
 
9. Please specify your current employment status  
Employed (full time)    Employed (part time)    
Retired      Unemployed  
 
Please specify your main occupation (current or previous): 
________________________________________________________________________________________ 
10. What subtype of Multiple Sclerosis have you been diagnosed with? 
Clinically isolated syndrome    Relapsing and remitting multiple sclerosis 
 
Benign multiple sclerosis    Secondary progressive multiple sclerosis 
 
Primary progressive multiple sclerosis   Not known 
11. When do you feel your symptoms of multiple sclerosis first started? (Please specify how many months or 
years) 
________________________________________________________________________________________  
12. How long ago were you diagnosed with multiple sclerosis? (Please specify how many months or years) 
______________________________________________________________________________________ __ 
13. Other than multiple sclerosis, do you have any long-term illnesses, health problems, or disabilities? 
(Please 
specify)__________________________________________________________________________________
________________________________________________________________________________________  
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Liverpool Self Efficacy Questionnaire 
 
Think about how you have been feeling over the last week. Please read the following 
statements and indicate the extent to which you agree or disagree with them by circling 
one answer to each question.  
 
 
  Strongly 
agree 
Agree Disagree Strongly 
Disagree 
1. Since my diagnosis was confirmed, my life has been 
beset with difficulties over which I have no control 
 
1 2 3 4 
2. I feel in control of my life 
 
4 3 2 1 
3. I rely on others to help me make decisions 
 
1 2 3 4 
4. Sometimes I feel that my MS controls my life 
 
1 2 3 4 
5. I often feel helpless when dealing with my difficulties 
 
1 2 3 4 
6. The way my MS affects me in the future mostly depends 
on me 
 
4 
 
3 2 1 
7. I worry about how I will cope in the future 
 
1 2 3 4 
8. Despite my difficulties, I still manage to cope with daily 
life 
 
4 3 2 1 
9. There is really no way I can solve some of the problems I 
have with my MS 
 
1 2 3 4 
10. Despite my MS, I can do anything I set my mind to 
 
4 3 2 1 
11. I am confident I can overcome my difficulties 
 
4 3 2 1 
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